title: Efficacy of mitoxantrone against various neoplasms in dogs.
abstract: One hundred twenty-six dogs with histologically confirmed, measurable malignant tumors were evaluated in a prospective study to determine the response to the antineoplastic drug mitoxantrone. Ninety-five dogs had been refractory to one or more treatment modalities (surgery, n = 57; chemotherapy other than mitoxantrone, n = 37; radiation, n = 4; whole body hyperthermia, n = 1). The extent of neoplastic disease was determined immediately before each dose of mitoxantrone was administered (1 to 10 doses, 2.5 to 5 mg/m2 of body surface area, IV) 21 days apart. Each dog was treated with mitoxantrone until the dog developed progressive disease or until the dog's quality of life diminished to an unacceptable level as determined by the owner or attending veterinarian. A partial or complete remission (greater than 50% volume reduction) was obtained in 23% (29/126) of all dogs treated. Tumors in which there was a partial or complete remission included lymphoma (11/32), squamous cell carcinoma (4/9), fibrosarcoma (2/9), thyroid carcinoma (1/10), transitional cell carcinoma (1/6), mammary adenocarcinoma (1/6), hepatocellular carcinoma (1/4), renal adenocarcinoma (1/1), rectal carcinoma (1/1), chondrosarcoma (1/2), oral malignant melanoma (1/12), cutaneous malignant melanoma (1/1), myxosarcoma (1/1), mesothelioma (1/1), and hemangiopericytoma (1/1). Our results indicated that mitoxantrone induces measurable regression in various malignant tumors in dogs.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: J E
authors.initials: JE
authors.lastname: Obradovich
authors.forename: R E
authors.initials: RE
authors.lastname: Elmslie
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.forename: A S
authors.initials: AS
authors.lastname: Moore
authors.forename: R C
authors.initials: RC
authors.lastname: Straw
authors.forename: K
authors.initials: K
authors.lastname: Dickinson
authors.forename: M F
authors.initials: MF
authors.lastname: Cooper
authors.forename: S J
authors.initials: SJ
authors.lastname: Withrow
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000188:drug therapy / Q000662:veterinary; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary; D008942:Mitoxantrone / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D011446:Prospective Studies; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy / Q000662:veterinary
chemical_list: D008942:Mitoxantrone